Glycation of serum albumin and its role in renal protein excretion and the development of diabetic nephropathy.
The present study was designed to investigate whether microalbuminuria at the onset of diabetic nephropathy might be partially due to the glycation of serum albumin. It is postulated elsewhere (Ghiggeri et al., Proc. Eur. Dial. Transplant. Assoc. 21 (1984) 633-636) that the glycation of serum albumin and the subsequent cationization may induce microalbuminuria. To investigate whether a relationship exists between the amount of glycated albumin in its cationized form and the development, and progression of diabetic nephropathy, the urinary excretion of glycated albumin was studied in diabetic patients. The diabetic patients (type I and II diabetes) were divided into groups according to their albumin excretion rates: group I diabetics had a normal albumin excretion (n = 30, x = 4.2 mg/12 h); group II diabetes displayed microalbuminuria (n = 17, x = 38.6 mg/12 h); group III diabetics displayed macroalbuminuria (n = 21, x = 582.5 mg/12 h). The fraction of glycated albumin in serum (Glyco Gel Test Kit) was 0.032 in group I, 0.042 in group II, and 0.038 in group III, all these values were significantly higher than the value for the controls (0.014%; n = 17, 2 alpha = 0.001) as measured with the Glyco Gel Test Kit. The concentration of glycated albumin in the urine of the controls and group I was below the detection limit. Urine in group II contained only a glycated albumin fraction of 0.0002 of total albumin, and the fraction for group III was 0.0008. Isoelectric focussing (IEF) and chromato-focussing revealed native albumin with an isoelectric point of 4.7-4.9, and anionic glycated albumin with a pI of 3.0-4.2.(ABSTRACT TRUNCATED AT 250 WORDS)
Bundschuh
I
I
Medical School Hannover, Department of Internal Medicine and Dermatology, Germany.
Jäckle-Meyer
I
I
Lüneberg
E
E
Bentzel
C
C
Petzoldt
R
R
Stolte
H
H
D000328:Adult; D000419:Albuminuria / Q000209:etiology / Q000652:urine; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000652:urine; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000652:urine; D003928:Diabetic Nephropathies / Q000175:diagnosis / Q000209:etiology / Q000652:urine*; D005260:Female; D017127:Glycation End Products, Advanced; D006031:Glycosylation; D006801:Humans; D007525:Isoelectric Focusing; D007668:Kidney / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011507:Proteinuria / Q000209:etiology / Q000503:physiopathology / Q000652:urine*; D012709:Serum Albumin / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology*; D000093423:Glycated Serum Albumin
D017127:Glycation End Products, Advanced; D012709:Serum Albumin; D000093423:Glycated Serum Albumin